The complex relationship between obesity and the somatropic axis: The long and winding road

Growth Hormone and IGF Research

Volumn 24, Issue 6, 2014, Pages 221-226

  Savastano, Silvia ^a   Di Somma, Carolina ^b   Barrea, Luigi ^c   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SDN   (Italy)

^c IOS and COLEMAN Srl   (Italy)

Author keywords

Body composition; Cardio metabolic risk; Obesity and GH IGF 1 axis

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

BARIATRIC SURGERY; BODY COMPOSITION; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; ENDOCRINE FUNCTION TEST; ENDOCRINE SYSTEM; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH HORMONE STIMULATION TEST; HORMONAL REGULATION; HUMAN; NONHUMAN; OBESITY; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; REVIEW; SOMATOTROPIC AXIS; TREATMENT OUTCOME; WEIGHT REDUCTION; METABOLISM; PATHOPHYSIOLOGY;

HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OBESITY;

EID: 84919483077     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2014.09.002     Document Type: Review

References (66)

1. Cannata D., Vijayakumar A., Fierz Y., LeRoith D. The GH/IGF-1 axis in growth and development: new insights derived from animal models. Adv. Pediatr. 2010, 57:331-351.
2. Dieguez C., Casanueva F.F. Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol. Metab. 1995, 6:55-59.
3. Vijayakumar A., Yakar S., LeRoith D. The intricate role of growth hormone in metabolism. Front. Endocrinol. 2011, 2:1-11. (Lausanne).
4. Reichlin S. Growth hormone content of pituitaries from rats with hypothalamic lesions. Endocrinology 1961, 69:225-230.
5. Veldhuis J.D., Iranmanesh A., Ho K.K., Waters M.J., Johnson M.L., Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 1991, 72:51-59.
6. Maccario M., Grottoli S., Procopio M., Oleandri S.E., Rossetto R., Gauna C., Arvat E., Ghigo E. The GH/IGF-I axis in obesity: influence of neuro-endocrine and metabolic factors. Int. J. Obes. Relat. Metab. Disord. 2000, 24:S96-S99.
7. Savastano S., Di Somma C., Mentone A., Savanelli M.C., De Leo M., Lombardi G., Colao A. GH insufficiency in obese patients. J. Endocrinol. Investig. 2006, 29:42-53.
8. Rasmussen M.H. Obesity, growth hormone and weight loss. Mol. Cell. Endocrinol. 2010, 316:147-153.
9. Berryman D.E., Gla C.A., List E.O., Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat. Rev. Endocrinol. 2013, 9:346-356.
10. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Vance M.L., Endocrine Society Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96:1587-1609.
11. Vottero A., Guzzetti C., Loche S. New aspects of the physiology of the GH-IGF-1 axis. Endocr. Dev. 2013, 24:96-105.
12. Hjortebjerg R., Frystyk J. Determination of IGFs and their binding proteins. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27:771-781.
13. Frystyk J. Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormon. IGF Res. 2004, 14:337-375.
14. Arafat A.M., Weickert M.O., Frystyk J., Spranger J., Schöfl C., Möhlig M., Pfeiffer A.F. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J. Clin. Endocrinol. Metab. 2009, 94:5093-5101.
15. Chia D.J. Minireview: mechanisms of growth hormone-mediated gene regulation. Mol. Endocrinol. 2014, 28:1012-1025.
16. Ahmed S.F., Farquharson C. The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins. J. Endocrinol. 2010, 206:249-259.
17. Kumar P.A., Chitra P.S., Lu C., Sobhanaditya J., Menon R. Growth hormone (GH) differentially regulates NF-kB activity in preadipocytes and macrophages: implications for GH's role in adipose tissue homeostasis in obesity. J. Physiol. Biochem. 2014, 70:433-440.
18. Kawai M., Rosen C.J. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J. Cell. Biochem. 2010, 111:14-19.
19. Miller K.K., Biller B.M., Lipman J.G., Bradwin G., Rifai N., Klibanski A. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J. Clin. Endocrinol. Metab. 2005, 90:768-774.
20. Franco C., Bengtsson B.A., Johannsson G. The GH/IGF-1 axis in obesity: physiological and pathological aspects. Metab. Syndr. Relat. Disord. 2006, 4:51-56.
21. Cuneo R.C., Salomon F., McGauley G.A., Sönksen P.H. The growth hormone deficiency syndrome in adults. Clin. Endocrinol. 1992, 37:387-397. (Oxf.).
22. Colao A., Di Somma C., Cuocolo A., Filippella M., Rota F., Acampa W., Savastano S., Salvatore M., Lombardi G. The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J. Clin. Endocrinol. Metab. 2004, 89:5998-6004.
23. van Bunderen C.C., van Varsseveld N.C., Erfurth E.M., Ket J.C., Drent M.L. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin. Endocrinol. 2014, 81:1-14. (Oxf).
24. Höybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Hormon. IGF Res. 2004, 14:1-15.
25. Stafler P., Wallis C. Prader-Willi syndrome: who can have growth hormone?. Arch. Dis. Child. 2008, 93:341-345.
26. Berryman D.E., List E.O., Coschigano K.T., Behar K., Kim J.K., Kopchick J.J. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm. IGF Res. 2004, 14:309-318.
27. Berryman D.E., List E.O., Sackmann-Sala L., Lubbers E., Munn R., Kopchick J.J. Growth hormone and adipose tissue: beyond the adipocyte. Growth Hormon. IGF Res. 2011, 21:113-123.
28. Utz A.L., Yamamoto A., Hemphill L., Miller K.K. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J. Clin. Endocrinol. Metab. 2008, 93:2507-2514.
29. Makimura H., Stanley T.L., Chen C., Wei J., Connelly J.M., Hemphill L.C., Grinspoon S.K. Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity. J. Clin. Endocrinol. Metab. 2009, 94:5131-5138.
30. Makimura H., Feldpausch M.N., Stanley T.L., Sun N., Grinspoon S.K. Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size. Clin. Endocrinol. 2012, 76:220-227. (Oxf).
31. Savastano S., Di Somma C., Belfiore A., Guida B., Jr Orio F., Rota F., Savanelli M.C., Cascella T., Mentone A., Angrisani L., Lombardi G., Colao A. Growth hormone status in morbidly obese subjects and correlation with body composition. J. Endocrinol. Investig. 2006, 29:536-543.
32. Di Somma C., Pivonello R., Pizza G., De Rosa A., Lombardi G., Colao A., Savastano A.S. Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J. Endocrinol. Investig. 2010, 33:171-177.
33. Makimura H., Stanley T.L., Mun D., You S.M., Grinspoon S.K. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. 2008, 93:4254-4260.
34. Cordido F., Peino R., Peñalva A., Alvarez C.V., Casanueva F.F., Dieguez C. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J. Clin. Endocrinol. Metab. 1996, 81:914-918.
35. Di Somma C., Rivellese A., Pizza G., Patti L., De Rosa A., Cipriano P., Nedi V., Rossi A., Lombardi G., Colao A., Savastano S. Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women. J. Endocrinol. Investig. 2011, 34:90-96.
36. Scacchi M., Orsini F., Cattaneo A., Grasso A., Filippini A., Pecori Giraldi B.F., Fatti L.M., Moro M., Cavagnini F. The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis. Eur. J. Endocrinol. 2010, 163:201-206.
37. Iranmanesh A., Lizarralde G., Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 1991, 73:1081-1088.
38. Colao A., Di Somma C., Cascella T., Pivonello R., Vitale G., Grasso L.F., Lombardi G., Savastano S. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur. J. Endocrinol. 2008, 159:389-397.
39. Akanji A.O., Smith R.J. The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab. Syndr. Relat. Disord. 2012, 10:3-13.
40. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Hormon. IGF Res. 2003, 13:113-170.
41. Frystyk J., Brick D.J., Gerweck A.V., Utz A.L., Miller K.K. Bioactive insulin-like growth factor- I in obesity. J. Clin. Endocrinol. Metab. 2009, 94:3093-3097.
42. Rasmussen M.H., Juul A., Hilsted J. Effect of weight loss on free insulin-like growth factor-I in obese women with hyposomatotropism. Obesity (Silver Spring) 2007, 15:879-886.
43. Völzke H., Nauck M., Rettig R., Dörr M., Higham C., Brabant G., Wallaschofski H. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur. J. Endocrinol. 2009, 161:705-713.
44. Savastano S., Di Somma C., Pizza G., De Rosa A., Nedi V., Rossi A., Orio F., Lombardi G., Colao A., Tarantino G. Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. J. Transl. Med. 2011, 9:136-143.
45. Tarantino G., Savastano S., Colao A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J. Gastroenterol. 2010, 16:4773-4783.
46. Stanley T.L., Feldpausch M.N., Murphy C.A., Grinspoon S.K., Makimura H. Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity. Growth Hormon. IGF Res. 2014, 24:10-15.
47. Di Somma C., Angrisani L., Rota F., Savanelli M.C., Cascella T., Belfiore A., Orio F., Lombardi G., Colao A., Savastano S. GH and IGF-I deficiency are associated with reduced loss of fat mass after laparoscopic-adjustable silicone gastric banding. Clin. Endocrinol. 2008, 69:393-399. (Oxf).
48. Pijl H., Langendonk J.G., Burggraaf J., Frölich M., Cohen A.F., Veldhuis J.D., Meinders A.E. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J. Clin. Endocrinol. Metab. 2001, 86:5509-5515.
49. Savastano S., Angrisani L., Di Somma C., Rota F., Savanelli M.C., Cascella T., Orio F., Lombardi G., Colao A. Relationship between growth hormone/insulin-like growth factor-1 axis integrity and voluntary weight loss after gastric banding surgery for severe obesity. Obes. Surg. 2010, 20:211-220.
50. Camastra S., Manco M., Frascerra S., Iaconelli A., Mingrone G., Ferrannini F. Daylong pituitary hormones in morbid obesity: effects of bariatric surgery. Int. J. Obes. 2009, 33:166-172. (Lond).
51. Mancini M.C., Costa A.P., de Melo M.-E., Cercato C., Giannella-Neto D., Garrido A.B., Rosberg S., Albertsson-Wikland K., Villares S.M., Halpern A. Effect of gastric bypass on spontaneous growth hormone and ghrelin release profiles. Obesity (Silver Spring) 2006, 14:383-387.
52. Galli G., Pinchera A., Piaggi P., Fierabracci P., Giannetti M., Querci G., Scartabelli G., Manetti L., Ceccarini G., Martinelli S., Di Salvo C., Anselmino M., Bogazzi F., Landi A., Vitti P., Maffei M., Santini F. Serum insulin-like growth factor-1 concentrations are reduced in severely obese women and raise after weight loss induced by laparoscopic adjustable gastric banding. Obes. Surg. 2012, 22:1276-1280.
53. Mittempergher F., Pata G., Crea N., Di Betta E., Vilardi A., Chiesa D., Nascimbeni R. Preoperative prediction of growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modification and postoperative changes in candidates for bariatric surgery. Obes. Surg. 2013, 23:594-601.
54. De Marinis L., Bianchi A., Mancini A., Gentilella R., Perrelli M., Giampietro A., Porcelli T., Tilaro L., Fusco A., Valle D., Tacchino R.M. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J. Clin. Endocrinol. Metab. 2004, 89:174-180.
55. Edén Engström B., Burman P., Holdstock C., Ohrvall M., Sundbom M., Karlsson F.A. Effects of gastric bypass on the GH/IGF-I axis in severe obesity-and a comparison with GH deficiency. Eur. J. Endocrinol. 2006, 154:53-59.
56. Stanley T.L., Levitsky L.L., Grinspoon S.K., Misra M. Effect of body mass index on peak growth hormone response to provocative testing in children with short stature. J. Clin. Endocrinol. Metab. 2009, 94:4875-4881.
57. Bredella M.A., Utz A.L., Torriani M., Thomas B., Schoenfeld D.A., Miller K.K. Anthropometry, CT, and DXA as predictors of GH deficiency in premenopausal women: ROC curve analysis. J. Appl. Physiol. 2009, 106:418-422.
58. Colao A., Di Somma C., Savastano S., Rota S.F., Savanelli M.C., Aimaretti G., Lombardi G. A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J. Clin. Endocrinol. Metab. 2009, 94:4414-4422.
59. Corneli G., Di Somma C., Baldelli R., Rovere R.S., Gasco V., Croce C.G., Grottoli S., Maccario M., Colao A., Lombardi G., Ghigo E., Camanni F., Aimaretti G. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur. J. Endocrinol. 2005, 153:257-264.
60. Dichtel L.E., Yuen K.C., Bredella M.A., Gerweck A.V., Russell B.M., Riccio A.D., Gurel M.H., Sluss P.M., Biller B.M., Miller K.K. Overweight/obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. Clin. Endocrinol. Metab. 2014, (Sep 11:jc20142830. [Epub ahead of print]).
61. Popovic V. Approach to testing growth hormone (GH) secretion in obese subjects. J. Clin. Endocrinol. Metab. 2013, 98:1789-1796.
62. Barrett J., Maranda L., Nwosu B.U. The relationship between subnormal peak-stimulated growth hormone levels and auxological characteristics in obese children. Front. Endocrinol. 2014, 5:35-41. (Lausanne).
63. Mekala K.C., Tritos N.A. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J. Clin. Endocrinol. Metab. 2009, 94:130-137.
64. Yuen K.C., Jr Roberts C.T., Frystyk J., Rooney W.D., Pollaro J.R., Klopfenstein B.J., Purnell J.Q. Short-term low-dose GH therapy improves insulin sensitivity without modifying cortisol metabolism and ectopic fat accumulation in adults with GH deficiency. J. Clin. Endocrinol. Metab. 2014, 99:1862-1869.
65. Savastano S., Di Somma C., Angrisani L., Orio F., Longobardi S., Lombardi G., Colao A. Growth hormone treatment prevents loss of lean mass after bariatric surgery in morbidly obese patients: results of a pilot, open, prospective, randomized, controlled study. J. Clin. Endocrinol. Metab. 2009, 94:817-826.
66. Makimura H., Feldpausch M.H., Rope A.M., Hemphill L.C., Torriani M., Lee H., Grinspoon S.K. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2012, 97:4769-4779.